{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:58:56Z","timestamp":1790366336836,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2017.00486","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T04:13:42Z","timestamp":1506312822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials"],"prefix":"10.3389","volume":"8","author":[{"given":"Syed I.","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Ampie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafeeq S.","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrn3689","article-title":"Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases","volume":"15","author":"Hetz","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"408681","DOI":"10.1155\/2013\/408681","article-title":"Redox regulation in amyotrophic lateral sclerosis","volume":"2013","author":"Parakh","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.4081\/ni.2015.5885","article-title":"Amyotrophic lateral sclerosis: new perspectives and update","volume":"7","author":"Orsini","year":"2015","journal-title":"Neurol Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"803701","DOI":"10.1155\/2012\/803701","article-title":"The neuroinflammatory response in ALS: the roles of microglia and T cells","volume":"2012","author":"Lewis","year":"2012","journal-title":"Neurol Res Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","article-title":"Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?","volume":"13","author":"Mitsumoto","year":"2014","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fncel.2015.00414","article-title":"The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"9","author":"Radford","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1172\/JCI90607","article-title":"Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia","volume":"127","author":"Lall","year":"2017","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2016","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1126\/science.1110647","article-title":"Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo","volume":"308","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0166-2236(02)02154-9","article-title":"Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases","volume":"25","author":"Neumann","year":"2002","journal-title":"Trends Neurosci"},{"key":"B12","volume-title":"Gene","year":"2004"},{"key":"B13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.nurt.2010.05.014","article-title":"Microglial activation and chronic neurodegeneration","volume":"7","author":"Lull","year":"2010","journal-title":"Neurotherapeutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/glia.1106","article-title":"Immune function of microglia","volume":"36","author":"Aloisi","year":"2001","journal-title":"Glia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1742-2094-11-98","article-title":"Neuroinflammation and M2 microglia: the good, the bad, and the inflamed","volume":"11","author":"Cherry","year":"2014","journal-title":"J Neuroinflammation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrendo.2014.208","article-title":"Insulin and IGF receptor signalling in neural-stem-cell homeostasis","volume":"11","author":"Ziegler","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1210\/en.2008-0920","article-title":"Expanding the mind: insulin-like growth factor I and brain development","volume":"149","author":"Joseph D\u2019Ercole","year":"2008","journal-title":"Endocrinology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.imbio.2008.11.009","article-title":"Alternative activation of macrophages: immune function and cellular biology","volume":"7","author":"Varin","year":"2014","journal-title":"Immunobiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aaf1064","article-title":"C9orf72 is required for proper macrophage and microglial function in mice","volume":"351","author":"O\u2019Rourke","year":"2016","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-0404.2011.01528.x","article-title":"Alterations of T cell subsets in ALS: a systemic immune activation?","volume":"125","author":"Rentzos","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"B21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/emmm.201201544","article-title":"Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival","volume":"5","author":"Henkel","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"31","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/archneur.1986.00520030026007","article-title":"Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations","volume":"43","author":"Appel","year":"1986","journal-title":"Arch Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00296-010-1760-3","article-title":"Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature","volume":"31","author":"Padovan","year":"2011","journal-title":"Rheumatol Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.neurol.2013.11.004","article-title":"Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis","volume":"170","author":"Bougea","year":"2014","journal-title":"Rev Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD005121","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis","volume":"1","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"13046","DOI":"10.1073\/pnas.1002396107","article-title":"Mutant superoxide dismutase 1-induced IL-1\u03b2 accelerates ALS pathogenesis","volume":"29","author":"Meissner","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0139684","DOI":"10.1371\/journal.pone.0139684","article-title":"Interleukin-1 antagonist Anakinra in amyotrophic lateral sclerosis \u2013 a pilot study","volume":"10","author":"Maier","year":"2015","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B31","first-page":"305","article-title":"Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling","volume":"1","author":"Mizwicki","year":"2012","journal-title":"Am J Neurodegener Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"324685","DOI":"10.1155\/2012\/324685","article-title":"Amyotrophic lateral sclerosis and multiple sclerosis overlap: a case report","volume":"2012","author":"Trojsi","year":"2012","journal-title":"Case Rep Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1756285611422108","article-title":"Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis","volume":"4","author":"Boster","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/17482960802195632","article-title":"A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS","volume":"9","author":"Gordon","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"B36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/17482960902803432","article-title":"Glatiramer acetate has no impact on disease progression in ALS at 40 mg\/day: a double- blind, randomized, multicentre, placebo-controlled trial","volume":"10","author":"Meininger","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"B37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B38","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","article-title":"Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis","volume":"13","author":"Potenza","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.84.14_supplement.P7.067","article-title":"A phase IIa double-blind, placebo-controlled study to evaluate the safety of oral fingolimod in patients with amyotrophic lateral sclerosis (ALS) (P7.067)","volume":"84","author":"Berry","year":"2015","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1191\/1352458504ms1070oa","article-title":"Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1\/Th2 balance and NKT cell subset in multiple sclerosis","volume":"10","author":"Feng","year":"2004","journal-title":"Mult Scler"},{"key":"B41","first-page":"4","article-title":"The microglial-motoneuron dialogue in ALS","volume":"30","author":"Appel","year":"2011","journal-title":"Acta Myol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P3.127","article-title":"Adaptive design single center phosphodiesterase type 4 (PDE4) inhibitor \u2013 ibudilast (MN-166-ALS-1201) phase 1b\/2a clinical trial double-blind (DB) with open label extension (OLE) [NCT02238626] for amyotrophic lateral sclerosis (ALS) patients [1] not requiring non-invasive ventilation (no NIV) up to 5 years (Early Cohort \u2013 EC) and [2] requiring non-invasive ventilation (NIV) up to 10 years (advanced NIV cohort \u2013 ANC) from disease onset \u2013 report of clinical trial DB, OLE and post-treatment cessation epochs \u2013 per-protocol (PP) treatment completion associated with improved survival and post treatment cessation loss of muscle strength (P3.127)","volume":"88","author":"Brooks","year":"2017","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"683a","DOI":"10.1016\/j.bpj.2011.11.3712","article-title":"Electrokinetically altered normal saline modulates ion channel activity","volume":"102","author":"Choi","year":"2012","journal-title":"Biophys J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e12261","DOI":"10.14814\/phy2.12261","article-title":"RNS60, a charge-stabilized nanostructure saline alters Xenopus laevis oocyte biophysical membrane properties by enhancing mitochondrial ATP production","volume":"3","author":"Choi","year":"2015","journal-title":"Physiol Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e51869","DOI":"10.1371\/journal.pone.0051869","article-title":"Protection of Tregs, suppression of Th1 and Th17\u2009cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline","volume":"7","author":"Mondal","year":"2012","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"29529","DOI":"10.1074\/jbc.M111.338012","article-title":"Suppression of nuclear factor-kappaB activation and inflammation in microglia by physically modified saline","volume":"287","author":"Khasnavis","year":"2012","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/archneur.1994.00540210031010","article-title":"Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy","volume":"51","author":"Dalakas","year":"1994","journal-title":"Arch Neurol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Ann Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/6568","article-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis","volume":"5","author":"Klivenyi","year":"1999","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tins.2008.02.002","article-title":"Novel roles for Nogo receptor in inflammation and disease","volume":"31","author":"David","year":"2008","journal-title":"Trends Neurosci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e0117355","DOI":"10.1371\/journal.pone.0117355","article-title":"Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies","volume":"10","author":"Berges","year":"2015","journal-title":"PLoS One"},{"key":"B53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1474-4422(16)30399-4","article-title":"Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"16","author":"Meininger","year":"2017","journal-title":"Lancet Neurol"},{"key":"B54","first-page":"365","article-title":"Development of WF10, a novel macrophage-regulating agent","volume":"3","author":"McGrath","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/omcr\/omv009","article-title":"Acute motor axonal neuropathy in a patient with prolonged CD4 depletion due to HIV: a local variant of macrophage activation syndrome?","volume":"2","author":"Dardis","year":"2015","journal-title":"Oxf Med Case Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/21678421.2014.951940","article-title":"NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study","volume":"15","author":"Miller","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1212\/NXI.0000000000000100","article-title":"Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS","volume":"2","author":"Miller","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1523\/JNEUROSCI.5253-05.2006","article-title":"Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"26","author":"Kiaei","year":"2006","journal-title":"J Neurosci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/17482960802709416","article-title":"Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial","volume":"10","author":"Stommel","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"B60","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00415-008-0756-3","article-title":"Thalidomide causes sinus bradycardia in ALS","volume":"255","author":"Meyer","year":"2008","journal-title":"J Neurol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/14660820410021311a","article-title":"Serum levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble endothelial leukocyte adhesion molecule-1(s-ELAM-1) in amyotrophic lateral sclerosis","volume":"6","author":"Rentzos","year":"2005","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"B62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1742-2094-8-74","article-title":"Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis","volume":"8","author":"Pollari","year":"2011","journal-title":"J Neuroinflammation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/17482960802588059","article-title":"Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis","volume":"10","author":"Zhang","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e17770","DOI":"10.1371\/journal.pone.0017770","article-title":"G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial","volume":"6","author":"Duning","year":"2011","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.nurt.2007.05.011","article-title":"Diffusion tensor imaging of the brain","volume":"4","author":"Alexander","year":"2007","journal-title":"Neurotherapeutics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3988\/jcn.2015.11.2.164","article-title":"Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study of Iranian patients","volume":"11","author":"Amirzagar","year":"2015","journal-title":"J Clin Neurol"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P3.137","article-title":"A phase 1 study assessing the infusion of expanded autologous regulatory T lymphocytes in subjects with amyotrophic lateral sclerosis (P3.137)","volume":"88","author":"Thonhoff","year":"2017","journal-title":"Neurology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0006-8993(01)02012-1","article-title":"Intrathecal cyclosporin prolongs survival of late-stage ALS mice","volume":"894","author":"Keep","year":"2001","journal-title":"Brain Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archneur.1988.00520280027011","article-title":"A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis","volume":"45","author":"Appel","year":"1988","journal-title":"Arch Neurol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/ana.410350205","article-title":"Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation","volume":"35","author":"Drachman","year":"1994","journal-title":"Ann Neurol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/0885066604267854","article-title":"Serious infections associated with anticytokine therapies in the rheumatic diseases","volume":"19","author":"Giles","year":"2004","journal-title":"J Intensive Care Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbadis.2010.07.007","article-title":"Inflammation, demyelination, and degeneration \u2013 recent insights from MS pathology","volume":"1812","author":"Stadelmann","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ejca.2007.07.015","article-title":"Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe","volume":"43","author":"Serraino","year":"2007","journal-title":"Eur J Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients\u2019 benefit-risk preferences: serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"J Neurol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1212\/WNL.0000000000003995","article-title":"Autologous hematopoietic stem cell transplantation for MS: safer than previously thought","volume":"88","author":"Burman","year":"2017","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/ene.13223","article-title":"Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson\u2019s disease","volume":"24","author":"Brockmann","year":"2017","journal-title":"Eur J Neurol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.18632\/aging.100801","article-title":"Metabolic profiling distinguishes three subtypes of Alzheimer\u2019s disease","volume":"7","author":"Bredesen","year":"2015","journal-title":"Aging"},{"key":"B78","volume-title":"The ALS C.A.R.E. Program","year":"1995"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:24:25Z","timestamp":1719469465000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":78,"alternative-id":["10.3389\/fneur.2017.00486"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2017.00486","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"article-number":"486"}}